205 related articles for article (PubMed ID: 16565509)
1. Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.
Arendt LM; Rose-Hellekant TA; Sandgren EP; Schuler LA
Am J Pathol; 2006 Apr; 168(4):1365-74. PubMed ID: 16565509
[TBL] [Abstract][Full Text] [Related]
2. TGFbeta1 and TGFalpha contrarily affect alveolar survival and tumorigenesis in mouse mammary epithelium.
Booth BW; Jhappan C; Merlino G; Smith GH
Int J Cancer; 2007 Feb; 120(3):493-9. PubMed ID: 17096338
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia.
Schroeder JA; Lee DC
J Mammary Gland Biol Neoplasia; 1997 Apr; 2(2):119-29. PubMed ID: 10882298
[TBL] [Abstract][Full Text] [Related]
4. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.
Arendt LM; Evans LC; Rugowski DE; Garcia-Barchino MJ; Rui H; Schuler LA
J Endocrinol; 2009 Oct; 203(1):99-110. PubMed ID: 19635758
[TBL] [Abstract][Full Text] [Related]
5. Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.
Arendt LM; Grafwallner-Huseth TL; Schuler LA
Am J Pathol; 2009 Mar; 174(3):1065-74. PubMed ID: 19179608
[TBL] [Abstract][Full Text] [Related]
6. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.
Arendt LM; Schuler LA
Am J Pathol; 2008 Jan; 172(1):194-202. PubMed ID: 18156207
[TBL] [Abstract][Full Text] [Related]
7. The effects of aromatase overexpression on mammary growth and gene expression in the aromatase x transforming growth factor alpha double transgenic mice.
Kirma N; Mandava U; Wuichet K; Tekmal RR
J Steroid Biochem Mol Biol; 2001 Nov; 78(5):419-26. PubMed ID: 11738552
[TBL] [Abstract][Full Text] [Related]
8. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.
O'Leary KA; Jallow F; Rugowski DE; Sullivan R; Sinkevicius KW; Greene GL; Schuler LA
Endocrinology; 2013 Dec; 154(12):4483-92. PubMed ID: 24064365
[TBL] [Abstract][Full Text] [Related]
9. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
Amundadottir LT; Leder P
Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037
[TBL] [Abstract][Full Text] [Related]
10. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
[TBL] [Abstract][Full Text] [Related]
11. Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.
Davies BR; Platt-Higgins AM; Schmidt G; Rudland PS
Am J Pathol; 1999 Jul; 155(1):303-14. PubMed ID: 10393862
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ
Mol Cell Biol; 1996 Oct; 16(10):5726-36. PubMed ID: 8816486
[TBL] [Abstract][Full Text] [Related]
13. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.
Rose-Hellekant TA; Arendt LM; Schroeder MD; Gilchrist K; Sandgren EP; Schuler LA
Oncogene; 2003 Jul; 22(30):4664-74. PubMed ID: 12879011
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor alpha and mouse models of human breast cancer.
Humphreys RC; Hennighausen L
Oncogene; 2000 Feb; 19(8):1085-91. PubMed ID: 10713694
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice.
Rose-Hellekant TA; Sandgren EP
Oncogene; 2000 Feb; 19(8):1092-6. PubMed ID: 10713695
[TBL] [Abstract][Full Text] [Related]
16. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma.
Manhès C; Kayser C; Bertheau P; Kelder B; Kopchick JJ; Kelly PA; Touraine P; Goffin V
J Endocrinol; 2006 Aug; 190(2):271-85. PubMed ID: 16899561
[TBL] [Abstract][Full Text] [Related]
17. Prolactin promotes mammary pathogenesis independently from cyclin D1.
Asher JM; O'Leary KA; Rugowski DE; Arendt LM; Schuler LA
Am J Pathol; 2012 Jul; 181(1):294-302. PubMed ID: 22658484
[TBL] [Abstract][Full Text] [Related]
18. Alterations in c-Src/HER1 and estrogen receptor α signaling pathways in mammary gland and tumors of hexachlorobenzene-treated rats.
Peña D; Pontillo C; García MA; Cocca C; Alvarez L; Chiappini F; Bourguignon N; Frahm I; Bergoc R; Kleiman de Pisarev D; Randi A
Toxicology; 2012 Mar; 293(1-3):68-77. PubMed ID: 22245120
[TBL] [Abstract][Full Text] [Related]
19. Strain background alters mammary gland lesion phenotype in transforming growth factor-alpha transgenic mice.
Rose-Hellekant TA; Gilchrist K; Sandgren EP
Am J Pathol; 2002 Oct; 161(4):1439-47. PubMed ID: 12368216
[TBL] [Abstract][Full Text] [Related]
20. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions.
Oakes SR; Robertson FG; Kench JG; Gardiner-Garden M; Wand MP; Green JE; Ormandy CJ
Oncogene; 2007 Jan; 26(4):543-53. PubMed ID: 16862169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
